Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study

Seasonal influenza causes substantial morbidity and mortality in China, which largely results from limited vaccine accessibility and poor vaccination coverage. Since 2013, Sanofi Pasteur’s facilities in Shenzhen, China have produced a trivalent inactivated influenza vaccine (Shz-IIV3) for each influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yuemei, Chu, Kai, Lavis, Nathalie, Li, Xiaoling, Liang, Bill, Liu, Shuzhen, Shao, Ming, Shu, Jean-Denis, Tabar, Cynthia, Samson, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605815/
https://www.ncbi.nlm.nih.gov/pubmed/30779689
http://dx.doi.org/10.1080/21645515.2019.1581541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605815/
https://www.ncbi.nlm.nih.gov/pubmed/30779689
http://dx.doi.org/10.1080/21645515.2019.1581541

Ejemplares similares